Patients with CDI given ridinilazole had sustained clinical response, fewer recurrences

Nearly three out of every four patients with Clostridioides difficile infection being treated with ridinilazole had a sustained clinical response, according to data presented at IDWeek.
“In addition to being effective for the treatment of C. difficile infection (CDI), there is a need for agents that can prevent CDI recurrences,” Pablo C. Okhuysen, MD, professor at the University of Texas MD Anderson Cancer Center told Healio. “A key factor predisposing to CDI recurrences is the intestinal dysbiosis that results from the use of nonselective antibiotics against CDI that also

Nearly three out of every four patients with Clostridioides difficile infection being treated with ridinilazole had a sustained clinical response, according to data presented at IDWeek.
“In addition to being effective for the treatment of C. difficile infection (CDI), there is a need for agents that can prevent CDI recurrences,” Pablo C. Okhuysen, MD, professor at the University of Texas MD Anderson Cancer Center told Healio. “A key factor predisposing to CDI recurrences is the intestinal dysbiosis that results from the use of nonselective antibiotics against CDI that also